Business Context and Reporting Period
This Form 6-K is filed by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) for the month of December 2018. The filing serves to incorporate Exhibit 99.1, which contains unaudited financial information for the six months ended June 30, 2018. The document was signed by Dr. Dalia Megiddo, Interim Chief Executive Officer, on December 31, 2018.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of an interim balance sheet and income statement in Exhibit 99.1 but does not reproduce the data within the body of this Form 6-K.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document focuses on the procedural incorporation of financial exhibits rather than analyzing performance trends.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or unusual items. The primary purpose of this submission is to meet Nasdaq Stock Market Rule 5250(c)(2) requirements regarding the submission of interim financial statements.
Investor Verification Checklist
- Verify the specific financial figures (revenue, expenses, cash position) in the attached Exhibit 99.1, as they are not listed in this summary text.
- Confirm the company's current name status, as the filing header lists "Bioblast Pharma Ltd." while metadata references "Enlivex Ltd."
- Review the unaudited nature of the financial data for the six months ended June 30, 2018.
- Check subsequent filings for updates on the interim CEO status and any changes to the registration statements on Form S-8.